Science Links Japan | Obstetrics and Gynecology

List of Jounal Titles

A to Z index of Journal Title. Choose a letter.

A/ B/ C/ D/ E/ F/ G/ H/ I/ J/ K/ L/ M/ N/ O/ P/ Q/ R/ S/ T/ U/ V/ W/ X/ Y/ Z/ 0/ 1/ 2/ 3/ 4/ 5/ 6/ 7/ 8/ 9

Obstetrics and Gynecology

Diagnosis and treatment for uteric corpus malignant tumors. I Endometrial hyperplasia. 1 Promotion of clinical diagnoses for the endometrial hyperplasia ; from clinical symptoms to pathological diagnosis.
Diagnosis and treatment for uteric corpus malignant tumors. I Endometrial hyperplasia. 2 Pathohistological diagnosis for the endometrial hyperplasia. 1 Practice of histological classification and pathological diagnosis.
Diagnosis and treatment for uteric corpus malignant tumors. I Endometrial hyperplasia. 2 Pathohistological diagnosis for the endometrial hyperplasia. 2 Differential diagnosis for atypical growth and highly-differentiated adenocarcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. I Endometrial hyperplasia. 3 Control and treatment for the endometrial hyperplasia. The therapy and selection.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 1 Promotion of clinical diagnosis for the endometrial carcinoma. 1 From clinical symptoms to pathological diagnosis.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 1 Promotion of clinical diagnosis for the endometrial carcinoma. 2 Significance and practice of endometrial cytodiagnosis.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 1 Promotion of clinical diagnosis for the endometrial carcinoma. 3 Ultrasonic findings.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 1 Promotion of clinical diagnosis for the endometrial carcinoma. 4 Uteroscopic findings.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 1 Total evaluation of the progress in the preoperation.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 2 Diagnosis for cervical invasion by uteroscopes.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 3 Evaluation of cervical invasion and tunica muscularis invasion by MRI.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 4 Metastatic diagnosis by CT and MRI.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 5 Evaluation of the lymph node by ultrasonic waves.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for the endometrial carcinoma and selection of the therapy. 6 Significance of blood tumor markers.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 2 Pre-treatment evaluation for endometrial carcinoma and selection of the therapy. 3 Operative therapy for the endometrial carcinoma and analysis of the pathohistological prognosticators.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 4 Postoperative progressive stage classification for the endometrial carcinoma ; explanation of progressive stage classification.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 5 Pathohistological diagnosis for the endometrial carcinoma. 1 Histological classification and practice of pathological diagnosis.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 5 Pathohistological diagnosis for the endometrial carcinoma. 2 Evaluation of pathohistological risk factors.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 6 Postoperative additional treatment for the endometrial carcinoma ; the indication and selection. 1 Selection of postoperative therapy by risk factors.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 6 Postoperative additional treatment for the endometrial carcinoma ; the indication and selection. 2 Radiotherapy.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 6 Postoperative additional treatment for the endometrial carcinoma ; the indication and selection. 3 Chemotherapy.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 6 Postoperative additional treatment for the endometrial carcinoma ; the indication and selection. 4 Hormonotherapy.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 7 Diagnosis and treatment for the special endometrial carcinoma. 1 Clear cell adenocarcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 7 Diagnosis and treatment for the special endometrial carcinoma. 2 Serous adenocarcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 7 Diagnosis and treatment for the special endometrial carcinoma. 3 Small cell carcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 8 Handling of the endometrial carcinoma in juvenile women.
Diagnosis and treatment for uteric corpus malignant tumors. II Endometrial carcinoma. 9 Follow-up of patients with the endometrial carcinoma and treatment for recurrent cancer.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 1 Promotion of clinical diagnosis for the uterine sarcoma. 1 Clinical findings, preoperative diagnosis and treatment plans.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 1 Promotion of clinical diagnosis for the uterine sarcoma. 2 Ultrasonic findings of the uterine sarcoma.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 1 Promotion of clinical diagnosis for the uterine sarcoma. 3 MRI findings of the uterine sarcoma.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 2 Pathohistological diagnosis for the uterine sarcoma ; leiomyoma, endometrial interstitial tumors and endothelical mesenchyme mixed tumors.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 3 Postoperative treatment for the uterine sarcoma. 1 Leiomyoma.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 3 Postoperative treatment for the uterine sarcoma. 2 Endometrial interstitial tumors.
Diagnosis and treatment for uteric corpus malignant tumors. III Uterine sarcoma (mesenchyme malignant tumors). 3 Postoperative treatment for the uterine sarcoma. 3 Malignant endothelical mesenchyme mixed tumors.
Diagnosis and treatment for uteric corpus malignant tumors. IV Villous diseases. 1 Diagnosis and control of vesicular mole ; diagnosis and treatment for invasive mole.
Diagnosis and treatment for uteric corpus malignant tumors. IV Villous diseases. 2 Pathohistological diagnosis for the villous diseases ; hydatidiform mole, choriocarcinoma and PSTT.
Diagnosis and treatment for uteric corpus malignant tumors. IV Villous diseases. 3 Handling of choriocarcinoma. 1 Promotion of clinical diagnoses and test method.
Diagnosis and treatment for uteric corpus malignant tumors. IV Villous diseases. 3 Handling of choriocarcinoma. 2 Chemotherapy and surgical therapy.
Diagnosis and treatment for uteric corpus malignant tumors. IV Villous diseases. 3 Handling of choriocarcinoma. 3 Treatment for the intractable choriocarcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 1 Natural history of endometrial hyperplasia.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 2 Epidemiology of endometrial carcinoma generation and risk factors.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 3 Biology of endometrial carcinoma and estrogen.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 4 Tamoxifen and endometrial carcinoma generation.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 5 Growth factors and the receptors in endometrial carcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 6 Gene alterations in endometrial carcinoma.
Diagnosis and treatment for uteric corpus malignant tumors. Pathology and molecular biology of endometrial carcinoma/ovarian cancer simultaneous existence cases.
Diagnosis and treatment for uteric corpus malignant tumors. Molecular genetics of uteric corpus carcinosarcoma ( carcinosarcoma ).
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 7 Molecular biology of uterine leiomyosarcoma.
Diagnosis and treatment for uteric corpus malignant tumors. V Basic knowledge of the uteric corpus malignant tumors. 8 Molecular biology of choriocarcinoma.
1
Ovarian cancer ; recent trends. 1. Epidemiology and risk factors of ovarian cancer generation.
Ovarian cancer ; recent trends. 2. Familial generation of ovarian cancer.
Ovarian cancer ; recent trends. 3. Molecular biology of ovarian cancer. Oncogenes and tumor supressor gene.
Ovarian cancer ; recent trends. 4. Screening of ovarian cancer.
Ovarian cancer ; recent trends. 5. Histopathology of ovarian tumors. 1. Boundary malignant tumors.
Ovarian cancer ; recent trends. 5. Histopathology for ovarian cancer. 2. Cancer.
Ovarian cancer ; recent trends. 5. Histopathology for ovarian cancer. 3. Malignancy diagnosis.
Ovarian cancer ; recent trends. 6. Surgical therapy for ovarian cancer. 1. Para aortic lymph node extirpation.
Ovarian cancer ; recent trends. 6. Surgical therapy for ovarian cancer. 2. Significance and problems of Second - L ook Operation ( SLO ).
Ovarian cancer ; recent trends. 7. Chemotherapy for ovarian cancer. 1. Paclitaxel ( Taxol ).
Ovarian cancer ; recent trends. 7. Chemotherapy for ovaran cancer. 2. Massive dose chemotherapy.
Ovarian cancer ; recent trends. 7. Chemotherapy for ovarian cancer. 3. Drug resistant cancer.
Ovarian cancer ; recent trends. 8. Diagnosis and treatment for ovarian boundary malignant tumors.
Ovarian cancer ; recent trends. 9. Functional preservation in therapy for ovarian cancer.
Woman internal medicine. Dehydration.
Epidemiology and prevention of menopause symptoms.
Study of laparoscopic operation for enormous ovarian tumors.
Clinical usefulness of Incadronate (YM175) tablets for patients with osteoporosis after menopause.
Used drugs for prevention of premature birth ; national investigation. Investigation by questionnaires.
Using experience of Ceprafilm for purpose of adhesion prevention after enucleatic myomectomy.
2
Reproduction and endocrine disrupting chemicals 1. Endocrine disrupting chemicals and health risk.
Reproduction and endocrine disrupting chemicals 2.Estrogen and endocrine disrupting chemicals.
Reproduction and endocrine disrupting chemicals 3.Regional differences of distribution of endocrine disrupting chemicals such as dioxin, etc.
Reproduction and endocrine disrupting chemicals 4.Reproduction disturbance of wild organisms and endocrine disrupting chemicals.
Reproduction and endocrine disrupting chemicals 5.Effect of endocrine disrupting chemicals on reproductive function.
Reproduction and endocrine disrupting chemicals 6.Sex differentiation fertility of fishes and endocrine disrupting chemicals.
Reproduction and endocrine disrupting chemicals 7.Problems of endocrine disrupting chemicals in livestock region.
Reproduction and endocrine disrupting chemicals 8.Correspondence of Environment Agency to problems of endocrine disrupting chemicals.
Hematuria and proteinuria.
Epidemiology and protective measure of mammary cancer.
A case of spondylocostal dysplasia diagnosed by prenatal ultrasound screening.
Clinical effect of combination therapy of hormone substitution therapy and active vitamin D 3 preparation Calcitriol for postmenopausal osteoporosis.
3
Infectious diseases in perinatal period Recent trends and countermeasures. 1. Toxoplasma.
Infectious diseasse in perinatal period Recent trends and countermeasures. 2. Pregnant women and rubella.
Infectious diseases in perinatal period Recent trends and countermeasures. 3. Cytomegalovirus.
Infectious diseases in perinatal period Recent trends and countermeasures. 4. Herpes simplex virus.
Infectious diseases in perinatal period Recent trends and countermeasures. 5. Hemolytic streptococcus B.
Infectious diseases in perinatal period Recent trends and countermeasures. 6. Listeria monocytogenes.
Infectious diseases in perinatal period Recent trends and countermeasures. 7. Chlamydia.
Infectious diseases in perinatal period Recent trends and countermeasures. 8. Hepatitis C virus and hepatitis B virus.
Infectious diseases in perinatal period Recent trends and countermeasures. 9. Parvovirus B19.
Infectious diseases in perinatal period Recent trends and countermeasures. 10. Human adult T cell leukemia virus (HTLV-I).
Infectious diseases in perinatal period Recent trends and countermeasures. 11. HIV.
Series on internal medicine in women. Abdominal pain.
Merits and demerits of hormone substitution therapy.
Clinical study of Retroperitoneal Lymph Node Metastasis in Ovarian Cancer.
Perinatal bacterial flora in relation to the appearance of GBS infection.
Results of external fertilization and embryo transfer by Long Protocol using nafarelin acetate Evaluation of usefulness for egg collection in fixed day.
4
Gynaecology operation series 48. Cervical cancer operative method ; history and basic idea 1.
Primary care of adolescence women 1. Adolescence outbreak mechanisms.
Primary care of adolescence women 2. Adolescence outbreak and melatonin.
Primary care of adolescence women 3. Adolescence outbreak and IGF.
Primary care of adolescence women 4. Body weights and sexual functions in adolescence women.
Primary care of adolescence women 5. Menstruation disorders in adolescence women.
Primary care of adolescence women 6. Adolescence women and bone metabolisms.
Primary care of adolescence women 7. Adolescence and sports.
Primary care of adolescence women 8. Adolescence women and STD.
Primary care of adolescence women 9. Adolescence women and contraception.
Woman internal medicine. Anemia.
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer.
A case of uterine inversion with placenta increta following vaginal delivery.
A case of giant malignant struma ovarii with postsurgical reexpansion pulmonary edema.
Study of Quick E3 Test.
5
Recent topics on embryonic growth and implantation. 1. Implantation period endometrium and cytokines.
Recent topics on embryonic growth and implantation. 2. Interactions between emryos and endometrium.
Recent topics on embryonic growth and implantation. 3. Embryonic growth and growth factors.
Recent topics on embryonic growth and implantation. 4. Embryonic adhesion and extracellular matrix.
Recent topics on embryonic growth and implantation. 5. Implantation and adhesive proteins.
Recent topics on embryonic growth and implantation. 6. Implantation and cellular growth factors.
Recent topics on embryonic growth and implantation. 7. Trophoblast growth and adhesive molecules.
Recent topics on embryonic growth and implantation. 8. Functional differentiation of trophoblasts.
Recent topics on embryonic growth and implantation. 9. Conception recognition in implantation process.
Woman internal medicine. Anorexia nervosa.
A procedure for the evaluation of victims of Sex Crimes and Post-coital Contraception.
A case of Retroperitoneal Malignant Fibrous Histiocytoma.
A case of cord entanglement in monoamniotic twin pregnancy.
Pregnancy with gastric cancer: A case report.
Usefulness of gradual reduction of Nasanyl ( nafarelin acetate ) in IVF - ET cycle.
6
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 1). Diagnosis for the hysteromyoma. Histological diversity and imaging.
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 2). Diagnosis by needle biopsy.
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 3). The hysteromyoma and sterility.
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 4). Individualization of therapy and informed consent.
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 5). New pharmacotherapy I. Gn - RHa/steroid hormone add - back Therapy.
Diagnosis and treatment for uterine mesenchymal tumors1. Hysteromyoma 6). New pharmacotherapy II. Long-term management of excess menses by norgestrel emission type IUD.
Diagnosis and treatment for uterine mesenchymal tumors 1. Hysteromyomas 7). New surgical remedy I. Laparoscopic operation.
Diagnosis and treatment for uterine mesenchymal tumors 1. Hysteromyomas 8). New surgical remedy II. Resectoscope.
Diagnosis and treatment for uterine mesenchymal tumors 2. Diagnosis and treatment for uterine adenomyosis.
Diagnosis and treatment for uterine mesenchymal tumors 3. Diagnosis and treatment for endometrial interstitial sarcoma.
Diagnosis and treatment for uterine mesenchymal tumors 4. Diagnosis and treatment for uterine cancer sarcoma ( carcinosarcoma ).
Diagnosis and treatment for uterine mesenchymal tumors 5. Diagnosis and treatment for uterine leiomyosarcoma.
Bronchial asthma.
A case of MRSA puerperal fever complicated with ARDS.
GnRH agonist pharmaceuticals. The characteristics and selected application.
Effect of DHA - S viginal suppository on fetal weeks and on parturition hours.
7
Indorn morphological abnormalities 1. Indorn morphological abnormalities in Japan.
Indorn morphological abnormalities 2. Human normal and abnormal occurrence and the mechanisms.
Indorn morphological abnormalities 3. Indorn morphological abnormalities and chromosomes.
Indorn morphological abnormalities 4. Occurrence mechanisms of the indorn morphological abnormalities in diabetes mellitus and the prevention.
Indorn morphological abnormalities 5. Environment and morphological abnormalities.
Indorn morphological abnormalities 6. Indorn morphological abnormality diagnosis in early pregnancy.
Indorn morphological abnormalities 7. Mental care of parents delivering children with the indorn morphological abnormalities.
Indorn morphological abnormalities 8. The indorn morphological abnormalities and advances on surgical therapy.
Indorn morphological abnormalities 9. Generation prevention for the indorn morphological abnormalities. Prevention of neural tube defect by folic acid.
Atopic dermatitis.
Four cases of trauma during pregnancy.
A case of pregnancy complicated by hypertrophic cardiomyopathy.
Management of fetal heart beat positive overian pregnancy by laparoscopic conservative surgery.
A case of pelvic tumor with a deep vein thrombosis.
A case of endometriosis treated by long term gradual decreasing therapy for GnRHa ( nafarelin ).
8
Recent topics on sex differentiation 1. Recent topics on sex differentiation to gametogony from asexual reproduction 1. From asexual reproduction to gametonony.
Recent topics on sex differentiation 2. Molecular biology of sex determination.
Recent topics on sex differentiation 3. Gonad formation.
Recent topics on sex differentiation 4. Fertilizing capacity for mammal spermatogenic cells.
Recent topics on sex differentiation 5. Sex differentiation abnormalities and the diagnosis.
Recent topics on sex differentiation 6. Sex differentiation in the brain.
Recent topics on sex differentiation 7. Genetic control for sexual behavior.
Recent topics on sex differentiation 8. Gender identity failures 1) Disease state and treatment.
Recent topics on sex differentiation 8. Gender identity failures 2). Ethical problems. Ethical problems on diagnosis and treatment for gender identity failures.
Recent topics on sex differentiation 8. Gender identity failures 3). Legal problems.
Insomnia.
Treatment of yolk sac tumor and ovarian function. A Report of 8 cases.
A case of congenital short-limbed dwarfism with an-osteoplasia of the cranial bones.
A case of complete hydatidiform mole with vulvar metastasis.
9
The 38the Uterine cancer workshop. Histological diagnostic criteria of specificl type cervical cancer.
The 38th Uterine cancer workshop. Treatment for initial stage of lesion of cervix of uterus For especially objective of preservation of pregnant ability. Conization for pregnant and nonpregnant women Treatment results and effect on future pregnancy and parturition.
The 38th Uterine cancer workshop. Treatment for initial stage of lesion of cervix of uterus For especially objective of preservation of pregnant ability. Method in laser treatments 1.
The 38th Uterine cancer workshop. Treatment for initial stage of lesion of cervix of uterus For especially objective of preservation of pregnant ability. Method in laser treatments. 2.
The 38th Uterine cancer workshop. Treatment for initial stage of lesion of cervix of uterus For especially objective of preservation of pregnant ability. Method in photodynamic therapy (PDT).
The 38th Uterine cancer workshop. Evaluation of adjuvant chemotherapy of uterine cancer In comparison with radiotherapy from the viewpoint of prognosis.
The 38th Uterine cancer workshop. Evaluation of adjuvant chemotherapy of uterine cancer In comparison with radiotherapy from the viewpoint of prognosis.Examination of postoperative adjuvant therapy for uterine cancer.
The 38th Uterine cancer workshop. Evaluation of adjuvant chemotherapy of uterine cancer In comparison with radiotherapy from the viewpoint of prognosis. Treatment and prognosis of uterine cancer in this department.
The 38th Uterine cancer workshop. Evaluation of adjuvant chemotherapy of uterine cancer In comparison with radiotherapy from the viewpoint of prognosis. Treatment results of uterine cancer postoperative therapy in this hospital.
Gout.
Genetic diagnosis and management of pregnant woman with myotonic dystrophy.
Laparoscopic gonadectomy in a case of testicular feminization.
Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid: A case report.
Multiple sclerosis during pregnancy: A case report.
A case of HELLP syndrome complicated with acute renal failure in the early postpartum-The changes of endothelial injury markers during plasma exchanges.
hCG contained in gonadotropin preparation for postmenopausal females Effect on biological activity evaluation.
10
Mother diseases and mother's milk nurture1. Epilepsy.
Mother diseases and mother's milk nurture 2. Circulatory diseases.
Mother diseases and mother's milk nurture 3. Thyroid diseases.
Mother diseases and mother's milk nurture 4. Collagen disease.
Mother diseases and mother's milk nurture 5. Diabetes mellitus.
Mother diseases and mother's milk nurture 6. Pregnancy toxemias.
Mother diseases and mother's milk nurture 7. Psychiatric disorders after delivery.
Mother diseases and mother's milk nurture 8. Puerperal infection.
Mother diseases and mother's milk nurture 9. Hepatitis B and C virus.
Mother diseases and mother's milk nurture 1 0 . Adult T cell leukemia.
Pollinosis.
Climacteric disorders managed with aromatherapy.
Candidal colonisation of oral, rectal mucosa, urine and corona glandis in women with vulvovaginal candidiasis and their male sexual parthers. I. Factors taking part in recurrent vulvovaginal candidiasis.
Management of pregnancies and deliveries complicated with hypertrophic obstructive cardiomyopathy: A case report on two patients.
Two cases of vulvar basal cell carcinoma.
A case of adenoma malignum of the uterine cervix.
Two cases of placental hemangioma complicated by acute hydramnion.
A case of Muellerian duct cyst.
11
Gynecologic cancer chemotherapy clinical practice. I. EBM and cancer chemotherapy.
Gynecologic cancer chemotherapy clinical practice. II. ICH - GCP, new GCP and cancer clinical trial.
Gynecologic cancer chemotherapy clinical practice. III. Informed consent on cancer therapy.
Gynecologic cancer chemotherapy clinical practice. IV. Types and characteristics of anticancer drugs ( chemotherapy ) used in gynecologia.
Gynecologic cancer chemotherapy clinical practice. V. Cancer chemotherapy and Q O L.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium" 1) Standard initial treatment : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 2) Gynecologic cancer chemotherapy cooperative research association protocols.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 3) Treatment for recurrent cancer : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium" 4) Techniques in each facilities. (1) Intravenous infusion chemotherapy (iv) camptothecin.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 4) Techniques in each facilities. (2) Intravenous infusion chemotherapy (iv). Taxol.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 4) Techniques in each facilities. (2) Intraperitoneal chemotherapy (ip). Carboplatin.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 4) Techniques in each facilities. (2) Intraperitoneal chemotherapy (ip).
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 4) Techniques in each facilities. (3) Ne o adjuvant chem o therapy.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 4) Techniques in each facilities. (3) Ne o adjuvant chem otherapy.
Gynecologic cancer chemotherapy clinical practice. I. Ovarian cancer "epithelium". 1) Techniques in each facilities. Intravenous infusion chemotherapy (iv).
Gynecologic cancer chemotherapy clinical practice. II. Uterine cancer. 1) Standard treatment : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. II. Uterine cancer. 2) Gynecologic cancer chemotherapy cooperative research association protocols.
Gynecologic cancer chemotherapy clinical practice. II. Uterine cancer. 3) Techniques in each facilities. Is postoperative chemotherapy effective for recurrent prevention ?
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 1) Standard treatment : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 2) Gynecologic cancer chemotherapy cooperative research association protocols.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 3) Significance of maintenance chemotherapy.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (1) Intravenous infusion chemotherapy (iv).
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (1) Intravenous infusion chemotherapy (iv). Radiation and chemotherapy combination.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (2) Arterial injection chemotherapy (ia) and ne o adjuvant chem o therapy.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (2) Neo adjuvant chem o therapy.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (3) Sal vage therapy. B O MP therapy and MEP therapy for progressive and recurrent cervical cancer.
Gynecologic cancer chemotherapy clinical practice. III. Cervical cancer. 4) Techniques in each facilities. (3) Including sa l vage therapy.
Gynecologic cancer chemotherapy clinical practice. IV. Villous diseases. 1) Standard treatment : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. IV. Villous diseases. 2) Techniques in each facilities.
Gynecologic cancer chemotherapy clinical practice. V. Vulval and vaginal diseases. 1) Standard treatment : Reviews and future therapy.
Gynecologic cancer chemotherapy clinical practice. V. Vulval and vaginal diseases. 2) Gynecologic cancer chemotherapy cooperative research association protocols ( vulval cancer protocols ).
Gynecologic cancer chemotherapy clinical practice. V. Vulval and vaginal diseases. 3) Techniques in each facilities.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy ). 1) Bone marrow control. (1) G - CSF.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy). 1) Bone marrow control. (2) M - CSF.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy). 1) Bone marrow control. (3) Techniques in each facilities.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy ). 2) Digestive symptoms. (1) HT3 blockers.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy). 2) Digestive symptoms. (2) Techniques in each facilities. Techniques in carboplatin administration.
Gynecologic cancer chemotherapy clinical practice. VI. Side effect countermeasures (support therapy). 3) Other side effect countermeasures (depilation, stomatitis and neurologic manifestation ). Techniques in each facilities.
Gynecologic cancer chemotherapy clinical practice. VII. Chemotherapy and hospital and clinics cooperation. 1) Reviews.
Gynecologic cancer chemotherapy clinical practice. VII. Chemotherapy and hospital and clinics cooperation. 2) Problems in cooperation of home and ambulatory treatment.
Gynecologic cancer chemotherapy clinical practice. VII. Chemotherapy and hospital and clinics cooperation. 3) Techniques in each facilities. (1) From the viewpoint of basis hospital.
Gynecologic cancer chemotherapy clinical practice. VII. Chemotherapy and hospital and clinics cooperation. 3) Techniques in each facilities. (2) From the viewpoint of practice. Roles of clinics and suggestion to present chemotherapy from the viewpoint of terminal stage medical care.
Gynecologic cancer chemotherapy clinical practice. VII. Chemotherapy and hospital and clinics cooperation. 4) Cancer relaxation medical care science ; cancer pain treatment.
Angina pectoris.
12
Regulation of Meiosis.
A case of a vulvar tumor arising in supernumerary breast tissue of the right labia majus.